Ubs Asset Management Americas Inc Alkermes Plc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 405,382 shares of ALKS stock, worth $11.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

405,382

Previous 260,876 55.39%

Holding current value

$11.7 Million

Previous $6.29 Million 80.47%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $3.33 Million - $4.13 Million	144,506 Added 55.39%	405,382 $11.3 Million
Q2 2024 Aug 13, 2024	BUY	$23.21 - $27.24 $1.52 Million - $1.78 Million	65,434 Added 33.48%	260,876 $6.29 Million
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $146,150 - $180,252	5,536 Added 2.92%	195,442 $5.29 Million
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $174,013 - $213,551	7,446 Added 4.08%	189,906 $5.27 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $839,987 - $988,384	-30,916 Reduced 14.49%	182,460 $5.11 Million
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $603,668 - $692,156	23,851 Added 12.58%	213,376 $6.02 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $139,757 - $167,148	6,370 Added 3.48%	189,525 $4.95 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $875,006 - $1.27 Million	-39,773 Reduced 17.84%	183,155 $4.09 Million
Q2 2022 Aug 12, 2022	BUY	$26.4 - $30.54 $11,800 - $13,651	447 Added 0.2%	222,928 $6.64 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $5.39 Million - $6.54 Million	-233,647 Reduced 51.22%	222,481 $5.85 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $4.23 Million - $6.33 Million	-197,201 Reduced 30.18%	456,128 $10.6 Million
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $2.63 Million - $3.62 Million	112,739 Added 20.85%	653,329 $20.1 Million
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $6.91 Million - $9.25 Million	-367,983 Reduced 40.5%	540,590 $13.3 Million
Q1 2021 May 14, 2021	BUY	$18.21 - $23.2 $7.47 Million - $9.52 Million	410,481 Added 82.41%	908,573 $17 Million
Q4 2020 Mar 01, 2021	BUY	$15.39 - $22.1 $678,622 - $974,499	44,095 Added 9.71%	498,092 $9.94 Million
Q3 2020 Nov 13, 2020	BUY	$16.16 - $20.66 $3.78 Million - $4.84 Million	234,080 Added 106.44%	453,997 $7.52 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $296,666 - $432,629	-22,289 Reduced 9.2%	219,917 $4.27 Million
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $267,507 - $435,058	20,483 Added 9.24%	242,206 $3.49 Million
Q4 2019 Feb 14, 2020	SELL	$17.29 - $21.74 $14.2 Million - $17.9 Million	-822,210 Reduced 78.76%	221,723 $4.52 Million
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $667,437 - $830,618	-34,210 Reduced 3.17%	1,043,933 $20.4 Million
Q2 2019 Aug 15, 2019	BUY	$21.47 - $37.33 $488,850 - $849,966	22,769 Added 2.16%	1,078,143 $0
Q1 2019 May 14, 2019	SELL	$28.4 - $36.49 $425,687 - $546,948	-14,989 Reduced 1.4%	1,055,374 $0
Q4 2018 Feb 13, 2019	BUY	$27.94 - $44.61 $559,191 - $892,824	20,014 Added 1.91%	1,070,363 $31.6 Million
Q3 2018 Nov 14, 2018	SELL	$38.6 - $46.12 $4.08 Million - $4.88 Million	-105,824 Reduced 9.15%	1,050,349 $0
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $625,232 - $791,714	-15,415 Reduced 1.32%	1,156,173 $0
Q1 2018 May 14, 2018	SELL	$53.61 - $67.26 $2.17 Million - $2.72 Million	-40,475 Reduced 3.34%	1,171,588 $0
Q4 2017 Feb 09, 2018	SELL	$47.69 - $55.39 $2.43 Million - $2.83 Million	-51,046 Reduced 4.04%	1,212,063 $0
Q3 2017 Nov 13, 2017	BUY	$49.16 - $54.45 $62.1 Million - $68.8 Million	1,263,109	1,263,109 $0

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Alkermes Plc. Transaction History